Gilead Sciences, Inc.
—- Market cap
- $179.56B
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $179.56B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
Decision snapshot: GILD stock price at discount vs BDX $144.81 current versus $205.52 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BDX's multiple
Implied fair value · at GILD's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 71% equity / 29% debt · EV / Revenue 3.05x · EV proxy / EBITDA proxy 13.21x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GILEAD SCIENCES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BECTON, DICKINSON AND COMPANY · implied price per share
Bear
$55.64
Base
$79.14
Bull
$110.83
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AbbVie Inc.
GILD vs ABBV
AMGEN INC
GILD vs AMGN
BRISTOL MYERS SQUIBB CO
GILD vs BMY
Merck & Co., Inc.
GILD vs MRK
PFIZER INC
GILD vs PFE
REGENERON PHARMACEUTICALS, INC.
GILD vs REGN
Johnson & Johnson
GILD vs JNJ
Medtronic plc
GILD vs MDT
DANAHER CORP /DE/
GILD vs DHR
STRYKER CORP
GILD vs SYK
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe GILD can sustain its superior margins and ROIC while closing the growth gap versus BDX, then GILD looks attractive on a relative basis because the earnings multiple is lower despite much stronger profitability.
On a P/E basis, GILD looks cheaper than BDX at 19.6x versus 30.2x, which supports a relative valuation discount argument. However, GILD is more expensive on P/S and EV/Revenue, so the gap is not uniformly favorable and appears driven by GILD’s stronger profitability rather than a broad across-the-board discount.
Supporting Metrics